JAZZ Stock Analysis: Jazz Pharmaceuticals | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 14.913m USD | 12M Return: 75.1% | IE00B4Q5ZN47 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 179M
EPS Trend: -49.4%
Qual. Beats: 0
Rev. Trend: 96.5%
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a Dublin, Ireland-based biopharmaceutical company founded in 2003 that identifies, develops, and commercializes pharmaceutical products across the United States, Europe, and international markets. The company operates within the specialty pharmaceuticals segment of the health care sector.
The companys commercial portfolio spans multiple therapeutic areas, including neuroscience (Xywav for narcolepsy and idiopathic hypersomnia, Epidiolex for seizure disorders), oncology (Rylaze, Enrylaze, Zepzelca, Ziihera, Modeyso, Vyxeos), and rare diseases (Defitelio). This diversified product mix across specialty and rare-disease indications is characteristic of mid-to-large biopharma companies seeking to balance growth and pipeline risk.
The development pipeline includes late-stage assets such as Zanidatamab (Phase 3) for HER2-positive gastroesophageal and biliary tract cancers and Dordaviprone for H3 K27M-mutant diffuse glioma, alongside earlier-stage candidates like JZP815, JZP898, JZP047, and JZP3507 in Phase 1 and 2 trials.
Jazz supplements its internal R&D with collaboration and licensing agreements with partners including Redx Pharma, Autifony Therapeutics, Zymeworks, Sumitomo Pharma, Werewolf Therapeutics, and AbCellera Biologics - a hybrid in-house and partnership model commonly used in the biopharmaceutical industry to broaden pipelines without absorbing full development costs.
- Xywav franchise faces generic erosion from Xyrem competition
- Epidiolex revenue growth offsets narcolepsy segment decline
- Zanidatamab Phase 3 HER2 cancer trial readout nears
| Net Income: 206.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.13 > 0.02 and ΔFCF/TA 1.34 > 1.0 |
| NWC/Revenue: 44.09% < 20% (prev 35.64%; Δ 8.45% < -1%) |
| CFO/TA 0.14 > 3% & CFO 1.69b > Net Income 206.0m |
| Net Debt (2.85b) to EBITDA (1.17b): 2.43 < 3 |
| Current Ratio: 1.82 > 1.5 & < 3 |
| Outstanding Shares: last quarter (64.7m) vs 12m ago 5.02% < -2% |
| Gross Margin: 88.17% > 18% (prev 85.39%; Δ 2.78% > 0.5%) |
| Asset Turnover: 40.40% > 50% (prev 36.61%; Δ 3.79% > 0%) |
| Interest Coverage Ratio: 2.36 > 6 (EBIT TTM 450.9m / Interest Expense TTM 191.3m) |
| A: 0.17 (Total Current Assets 4.61b - Total Current Liabilities 2.53b) / Total Assets 12.0b |
| B: 0.04 (Retained Earnings 423.6m / Total Assets 12.0b) |
| C: 0.04 (EBIT TTM 450.9m / Avg Total Assets 11.7b) |
| D: 0.54 (Book Value of Equity 4.19b / Total Liabilities 7.81b) |
| Altman-Z'' = 2.08 = BBB |
| DSRI: 1.01 (Receivables 873.7m/764.4m, Revenue 4.72b/4.16b) |
| GMI: 0.97 (GM 85.39% / 88.17%) |
| AQI: 0.91 (AQ_t 0.59 / AQ_t-1 0.65) |
| SGI: 1.13 (Revenue 4.72b / 4.16b) |
| TATA: -0.12 (NI 206.0m - CFO 1.69b) / TA 12.0b) |
| Beneish M = -3.02 (Cap -4..+1) = AA |
As of November 08, 2026, the stock is trading at USD 234.76 with a total of 886,982 shares traded. Over the past week, the price has changed by +8.70%, over one month by +1.46%, over three months by -8.53% and over the past year by +75.13%.
Current recommended Stop Loss: 219.10 (which is 6.7% or 2.1 ATR below the current price).
Jazz Pharmaceuticals has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy JAZZ.
- StrongBuy: 13
- Buy: 7
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 295.8 | 26% |
P/E Trailing = 63.4641
P/E Forward = 9.6993
P/S = 3.2412
P/B = 2.8981
P/EG = 0.9582
Revenue TTM = 4.72b USD
EBIT TTM = 450.9m USD
EBITDA TTM = 1.17b USD
Long Term Debt = 4.33b USD (from longTermDebt, last fiscal year)
Short Term Debt = 1.03b USD (from shortTermDebt, last quarter)
Debt = 5.70b USD (from shortLongTermDebtTotal, last quarter) + Leases 57.9m
Net Debt = 2.85b USD (calculated: Debt 5.70b - CCE 2.86b)
Enterprise Value = 17.8b USD (14.9b + Debt 5.70b - CCE 2.86b)
Interest Coverage Ratio = 2.36 (Ebit TTM 450.9m / Interest Expense TTM 191.3m)
EV/FCF = 11.29x (Enterprise Value 17.8b / FCF TTM 1.57b)
FCF Yield = 8.86% (FCF TTM 1.57b / Enterprise Value 17.8b)
FCF Margin = 33.34% (FCF TTM 1.57b / Revenue TTM 4.72b)
Net Margin = 4.37% (Net Income TTM 206.0m / Revenue TTM 4.72b)
Gross Margin = 88.17% ((Revenue TTM 4.72b - Cost of Revenue TTM 558.0m) / Revenue TTM)
Gross Margin QoQ = 91.10% (prev 90.37%)
Tobins Q-Ratio = 1.48 (Enterprise Value 17.8b / Total Assets 12.0b)
Interest Expense / Debt = 3.35% (Interest Expense 191.3m / Debt 5.70b)
Taxrate = 20.64% (53.6m / 259.6m)
NOPAT = 357.8m (EBIT 450.9m * (1 - 20.64%))
Current Ratio = 1.82 (Total Current Assets 4.61b / Total Current Liabilities 2.53b)
Debt / Equity = 1.36 (Debt 5.70b / totalStockholderEquity, last quarter 4.19b)
Debt / EBITDA = 2.43 (Net Debt 2.85b / EBITDA 1.17b)
Debt / FCF = 1.81 (Net Debt 2.85b / FCF TTM 1.57b)
Total Stockholder Equity = 4.46b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.76% (Net Income 206.0m / Total Assets 12.0b)
RoE = 4.62% (Net Income TTM 206.0m / Total Stockholder Equity 4.46b)
RoCE = 5.13% (EBIT 450.9m / Capital Employed (Equity 4.46b + L.T.Debt 4.33b))
RoIC = 3.49% (NOPAT 357.8m / Invested Capital 10.3b)
WACC = 5.91% (E(14.9b)/V(20.6b) * Re(7.15%) + D(5.70b)/V(20.6b) * Rd(3.35%) * (1-Tc(0.21)))
Discount Rate = 7.15% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 12.21 | Cagr: -3.21%
[DCF] Terminal Value 77.97% ; FCFF base≈1.48b ; Y1≈1.69b ; Y5≈2.49b
[DCF] Fair Price = 534.3 (EV 37.5b - Net Debt 2.85b = Equity 34.7b / Shares 64.9m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -49.45 | EPS CAGR: -27.77% | SUE: 0.20 | # QB: 0
Revenue Correlation: 96.47 | Revenue CAGR: 7.53% | SUE: -0.66 | # QB: 0
EPS current Quarter (2027-03-31): EPS=6.13 | Chg30d=+10.93% | Revisions=+0% | Analysts=4
EPS current Year (2026-12-31): EPS=15.00 | Chg30d=-17.38% | Revisions=-67% | GrowthEPS=+79.0% | GrowthRev=+12.6%
EPS next Year (2027-12-31): EPS=26.00 | Chg30d=+21.06% | Revisions=+0% | GrowthEPS=+73.4% | GrowthRev=+5.3%
[Analyst] Revisions Ratio: -35% (up=4, down=10)